BioMed Research International

Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives


Publishing date
01 Jun 2019
Status
Published
Submission deadline
25 Jan 2019

Lead Editor

1University of Florence, Florence, Italy

2University Hospital of Geneva, Geneva, Switzerland

3University of Modena and Reggio Emilia, Modena, Italy

4SS Annunziata Hospital, Cento, Italy

5University of Valencia, Valencia, Spain


Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives

Description

Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are main causes of chronic liver disease in the Western countries. Both ALD and NAFLD represent a broad spectrum of disorders ranging from simple steatosis to steatohepatitis and cirrhosis. ALD is caused by acute or chronic alcohol consumption while NAFLD is defined as the presence of hepatic steatosis in the absence of other causes of secondary fat accumulation such as significant alcohol consumption or hereditary disorders. NAFLD is a complex disease with genetic and environmental factors, being often associated with metabolic risk factors such as obesity and diabetes. Remarkably, the binge drinking represents a growing specific alcohol consumption pattern. The binge drinking is at the same time a predictor of fibrosis progression and a consolidated risk factor for obesity representing an ideal “common land” between ALD and NAFLD. In the recent years, new diagnostic tools and many experimental drugs have been proposed for both ALD and NAFLD.

We mainly welcome scientists to contribute with original, clinical studies, and review articles describing the state of the art of diagnostic and pharmacological issues regarding both ALD and NAFLD. This special issue aims to interest both practitioners and researchers in the areas of hepatology, gastroenterology, internal medicine, and toxicology.

Potential topics include but are not limited to the following:

  • Preventive health policies for alcoholic and nonalcoholic liver disease
  • Main tools for early diagnosis of steatosis and steatohepatitis
  • Diagnostic approach toward alcoholic and nonalcoholic advanced liver disease: similitudes and differences
  • New perspectives for the treatment of alcohol use disorder
  • Experimental drugs for nonalcoholic liver disease: lights and shadows
  • Psychological interventions for patients with alcohol-related or metabolic liver disease
  • Binge drinking: diagnostic approach and treatment options

Articles

  • Special Issue
  • - Volume 2019
  • - Article ID 8691502
  • - Editorial

Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives

Stefano Gitto | Florian Bihl | ... | Marina Berenguer
  • Special Issue
  • - Volume 2019
  • - Article ID 7465272
  • - Research Article

Hepatoprotective Effect of Jianpi Huoxue Formula on Nonalcoholic Fatty Liver Disease Induced by Methionine-Choline-Deficient Diet in Rat

Yu Feng | Yan Chen | ... | Simon Ming Yuen Lee
  • Special Issue
  • - Volume 2019
  • - Article ID 9846919
  • - Research Article

The Use of Antifibrotic Recombinant nAG Protein in a Rat Liver Fibrosis Model

Maha M. Arafah | Mohammad M. Al-Qattan | ... | Hend S. Almalki
  • Special Issue
  • - Volume 2019
  • - Article ID 3646975
  • - Research Article

Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics

Lech Chrostek | Dagmara Przekop | ... | Bogdan Cylwik
  • Special Issue
  • - Volume 2019
  • - Article ID 3951574
  • - Research Article

Transient Elastography and Ultrasonography: Optimal Evaluation of Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty Liver Disease

Geng-lin Zhang | Qi-yi Zhao | ... | Zhi-liang Gao
  • Special Issue
  • - Volume 2019
  • - Article ID 9583790
  • - Research Article

Nonalcoholic Fatty Liver Disease Aggravated the Severity of Acute Pancreatitis in Patients

Dacheng Wu | Min Zhang | ... | Weiming Xiao
  • Special Issue
  • - Volume 2019
  • - Article ID 8507583
  • - Review Article

Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease

Gemma Aragonès | Sergio González-García | ... | Teresa Auguet
BioMed Research International
 Journal metrics
Acceptance rate30%
Submission to final decision68 days
Acceptance to publication32 days
CiteScore3.600
Impact Factor2.276
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.